Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 8:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Medication Administration Clear all
Completed Phase 2Phase 3 Interventional Results available

PRecision Interventions for SMoking in the SCCS

NCT03521141
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Nicotine patch, Varenicline, Nicotine metabolism, Genetically-informed lung cancer risk score, NCI "Clearing the Air"
Drug · Genetic · Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Women's Opioid Treatment Follow-up Study

NCT05776966
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Gender-specific digital intervention (GSDI), Treatment as usual
Behavioral · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 9, 2026, 8:20 AM EDT
Terminated Phase 1 Interventional

A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

NCT04999202
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY2416964, Pembrolizumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Altamonte Springs, Florida • Sarasota, Florida • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacodynamics (PD) of Prednisoline in Healthy Male Subject

NCT03196557
View directory record Official record
Conditions
Immunoscience
Interventions
Prenisolone, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Sep 9, 2026, 8:20 AM EDT
Completed No phase listed Observational

Complementary and Alternative Medicine Use in Low-Income African American and Caucasian Adults With Asthma

NCT00094419
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2008 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Not applicable Interventional

The Diabetes Medication Adherence Promotion Intervention Trial

NCT02458495
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes MAP Intervention
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects

NCT01088919
View directory record Official record
Conditions
Healthy, Pharmacokinetics of ASP1941
Interventions
ASP1941, pioglitazone hydrochloride
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Night Respite for Postpartum Mothers With SUD

NCT05746507
View directory record Official record
Conditions
Opioid Use Disorder, Maternal Drugs Affecting Fetus, Postpartum Mood Disturbance, Sleep Disorder, Neonatal Opioid Withdrawal
Interventions
Night Respite Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Mattapan, Massachusetts • Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Phase 3 Interventional Results available

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

NCT01972841
View directory record Official record
Conditions
Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
Interventions
Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
3,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Phase 3 Interventional Results available

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

NCT01639495
View directory record Official record
Conditions
Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation
Interventions
THERMOCOOL® SMARTTOUCH™ Catheter
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Birmingham, Alabama • Stanford, California • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 9, 2026, 8:20 AM EDT
Not listed No phase listed Observational

Early Prostate Cancer: Predicting Treatment Response

NCT03770351
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Tablet-Aided BehavioraL Intervention EffecT on Self-management Skills

NCT02128854
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Type II
Interventions
Tablets Intervention
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
45 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

NCT00001131
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin, HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis

NCT02063672
View directory record Official record
Conditions
Femoral Artery Stenosis, Femoral Artery Occlusion, Restenosis
Interventions
Lutonix DCB, Standard Uncoated Balloon Angioplasty Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
20
States / cities
Fairhope, Alabama • New Haven, Connecticut • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Phase 2 Interventional

Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence

NCT00548275
View directory record Official record
Conditions
Opiate Dependence, HIV Infections
Interventions
Enhanced Sexual Risk Management, Standard Sexual Risk Management
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

NCT01327651
View directory record Official record
Conditions
HIV Infections
Interventions
Daily dosing, Time-driven dosing, Event-driven dosing
Drug
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Phase 3 Interventional

NATIENS: Optimal Management and Mechanisms of SJS/TEN

NCT02987257
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions
Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

NCT01691807
View directory record Official record
Conditions
Cancer
Interventions
ofatumumab, bendamustine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Birmingham, Alabama • Southaven, Mississippi • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 9, 2026, 8:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 9, 2026, 8:20 AM EDT
Recruiting Phase 1 Interventional

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06896916
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig, Iberdomide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
7
States / cities
Beverly Hills, California • Denver, Colorado • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft

NCT02592330
View directory record Official record
Conditions
Limbal Stem Cell Deficiency
Interventions
Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant
Procedure · Biological
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Mobile After-Care Intervention to Support Post-Hospital Transition (MACS)

NCT03769493
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Mobile After-Care Support (MACS) app
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects

NCT06064539
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tolebrutinib, gemfibrozil, rifampicin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 9, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Adolescent Interventions to Manage Self-regulation of T1D (AIMS T1D)

NCT03688919
View directory record Official record
Conditions
Self-regulation, Medication Adherence
Interventions
Self-Regulation Intervention
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 17 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 9, 2026, 8:20 AM EDT